Intravenous (IV) Ibuprofen Market

Market Overview:

The global intravenous (IV) ibuprofen market size reached US$ 6.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.79% during 2024-2032.

Ibuprofen belongs to the nonsteroidal anti-inflammatory drug (NSAID) class used to treat inflammation, pain, and fever. It inhibits cyclooxygenase COZ-1 and COX-2 enzymes that are required for the synthesis of prostaglandins (PG). Intravenous (IV) ibuprofen is used alone or with other medicines to relieve mild to severe discomfort. It is injected directly into the vein to block the body's production of certain natural substances that cause inflammation. It helps to reduce narcotic analgesic requirements and lower pain levels with an excellent safety profile. IV ibuprofen also aids in improving pain control and reducing the usage of opioid drugs in orthopedic and abdominal surgeries and fever.

Intravenous (IV) Ibuprofen Market Trends:

The steadily rising geriatric population and the increasing prevalence of arthritis, cardiovascular diseases (CVDs), and cancer across the globe are creating a positive outlook for the market. In line with this, the widespread product adoption to manage and treat inflammatory diseases, rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, and osteoarthritis is favoring the market growth. Moreover, hectic working schedules and unhealthy lifestyles, along with a consequent decline in physical activity and proper nutrition, have led to a rise in the incidences of chronic diseases, which is acting as another growth-inducing factor. Apart from this, the increasing product utilization to treat mild fever, dental pain, gastrointestinal pain, and ductus arteriosus in pediatrics is providing an impetus to the market growth. Moreover, IV ibuprofen is employed to relieve muscle or rheumatic pain, backache, neuralgia, sprains, strains, sports injuries, and musculoskeletal diseases, which is facilitating the market growth. Furthermore, the increasing demand for IV ibuprofen in orthopedic patients post knee or hip replacement surgeries to reduce pain and morphine use is positively influencing the market growth. Other factors, including significant improvements in the healthcare infrastructure, growing health consciousness among individuals, and the rising expenditure capacities of consumers, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global intravenous (IV) ibuprofen market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product dose, indication and age group.

Breakup by Product Dose:

• 100 Mg Dose
• 200 Mg Dose
• 400 Mg Dose
• 800 Mg Dose
   

Breakup by Indication:

• Pain/Inflammatory
• Fever
   

Breakup by Age Group:

• Pediatrics
• Adults
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA and Xgen Pharmaceuticals Djb Inc.

Report Coverage: